Liquidity and going-concern risk
The company has limited cash and needs additional capital to continue operations and commercialization.
- Scope
- Core operations and product development
- Materiality
- high
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is a U.S.-based medical technology company developing TAEUS, a thermo-acoustic enhanced ultrasound platform designed to measure liver fat at the point of care. The company’s first application targets metabolic disease detection and management, including support for GLP-1 therapy eligibility and monitoring, but it has not yet commercialized the technology or generated revenue.
1.29
1.29
| % | |
|---|---|
| TAEUS diagnostic platform | 0% Thermo-acoustic enhanced ultrasound systems and related software for liver fat measurement. |
| Metabolic disease assessment applications | 0% Clinical applications aimed at detecting and managing metabolic disease biomarkers. |
| GLP-1 management applications | 0% Tools intended to support patient selection and monitoring for GLP-1 therapies. |
| Subscription and service model | 0% Planned recurring-access model with monthly fees, upgrades, and maintenance. |
| Direct product sales | 0% Traditional sale of the device to customers that prefer an upfront purchase model. |
ENDRA is targeting clinical buyers that need a simple, point-of-care way to assess liver fat and related metabolic...
- Point-of-care cliniciansprimary
Buy TAEUS to measure liver fat quickly in office or clinic settings and support diagnosis.
- Metabolic disease management programsprimary
Use the platform to identify and track biomarkers tied to obesity, NAFLD, and related conditions.
- GLP-1 therapy providerssecondary
Use the device to help determine eligibility and monitor patients receiving GLP-1 treatments.
- Hospitals and imaging centerssecondary
May adopt the system for broader ultrasound-based assessment workflows and procedural use cases.
ENDRA is headquartered in the United States and appears to conduct most of its development, financing, and...
- •Headquartered in the United States
- •Commercialization and regulatory work are centered on U.S. markets
- •No disclosed country revenue because the product is not yet sold
- •Exposure is tied to U.S. FDA approval and domestic capital access
- •Future sales could expand internationally after initial U.S. launch
ENDRA’s strategy is to complete clinical development and obtain FDA approval for its NAFLD/liver-fat TAEUS system, then...
01
FDA approval and clinical validationshort-term
Commercial launch depends on proving safety, accuracy, and clinical utility.
02
Subscription-based commercializationmedium-term
Recurring revenue could lower customer adoption barriers and improve visibility.
03
Product simplification and AI enhancementmedium-term
Better usability and accuracy are needed to compete in point-of-care imaging.
ENDRA remains pre-revenue and depends on external financing to fund development, so liquidity risk is the dominant...
Regulatory approval risk
TAEUS must obtain FDA approval before broad commercialization of the NAFLD system.
- Scope
- Product launch timing and market access
- Materiality
- high
Clinical validation and adoption risk
The platform must prove accuracy, utility, and ease of use versus existing imaging alternatives.
- Scope
- Customer adoption and pricing power
- Materiality
- high
Cryptocurrency price and regulatory risk
The company intends to hold digital assets, which can be highly volatile and may face securities-law scrutiny.
- Scope
- Treasury assets and future offering proceeds
- Materiality
- medium
Warrant liability fair value
Can materially distort net loss from quarter to quarter
Share-based compensation
Raises operating expenses without affecting cash immediately
Going-concern assessment
Affects investor assessment of solvency and dilution risk
Fair value estimates and contingencies
Can change reported liabilities and expenses materially
: 28.4.2026